Frontlight ResearchEarly access
Taking people in NetherlandsPhase 1
Tests how a drug enters tumours in people with lung or neuroendocrine cancer
Tests BI 764532 in adults with small-cell lung cancer or related neuroendocrine cancers.
Key facts
- Who runs it
- Boehringer Ingelheim International GmbH
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- EU 2022-501818-54-00
- U1111-1291-7129
- Registry title
- A study to test how BI 764532 is taken up by tumours in people with small-cell lung cancer or neuroendocrine cancer
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 12 people, planned
- Started
- 22 Feb 2024
- Expected to end
- 25 Nov 2026
- Type of study
- Interventional
- Record updated
- 15 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with small-cell lung cancer or neuroendocrine cancer. It tests how the study drug BI 764532 is taken up by tumours.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC) or small cell carcinoma of any other origin, or large cell neuroendocrine lung carcinoma (LCNEC).
Main reasons for not taking part
- Healthy volunteers cannot join.
Where in Netherlands
- Amsterdam UMCAmsterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests how a drug enters tumours in people with lung or neuroendocrine cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 15 May 2026